Pharmacological Treatment of Generalised Anxiety Disorder: Current Practice and Future Directions

References

• Crocq MA. The history of generalized anxiety disorder as a diagnostic category. Dialogues Clin Neurosci. 2017;19(2):107–116.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed ed. (WA) DC: American Psychiatric Association; 1980.
   Google Scholar
• World Health Organization (WHO). The ICD-10 Classification of Mental and Behavioural Disorders. Genève Switzerland: World Health Organization (WHO); 1993.
   Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed ed. Arlington VA: American Psychiatric Association; 2013.
   Google Scholar
• World Health Organization (WHO). ICD-11: international Classification of Diseases. 11th ed ed. Genève Switzerland: World Health Organization (WHO); 2022.
   Google Scholar
• Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of twelve-month DSM-IV disorders in the national comorbidity survey replication (NCS-R). Arch Gen Psychiatry. 2005;62(6):617–627. DOI:10.1001/archpsyc.62.6.617
   PubMed Web of Science ®Google Scholar
• Wittchen HU, Jacobi F. Size and burden of mental disorders in Europe—a critical review and appraisal of 27 studies. Eur Neuropsychopharmacol. 2005;15(4):357–376.
   PubMed Web of Science ®Google Scholar
• Ruscio AM, Hallion LS, Lim CCW, et al. Cross-sectional comparison of the epidemiology of DSM-5 generalized anxiety disorder across the globe. JAMA Psychiatry. 2017;74(5):465–475. DOI:10.1001/jamapsychiatry.2017.0056
   PubMed Web of Science ®Google Scholar
• Santomauro DF, Mantilla Herrera AM, Shadid J. COVID-19 mental disorders collaborators. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet. 2021;398(10312):1700–1712.
   PubMed Web of Science ®Google Scholar
• Moreno-Peral P, Conejo-Cerón S, Motrico E, et al. Risk factors for the onset of panic and generalised anxiety disorders in the general adult population: a systematic review of cohort studies. J Affect Disord. 2014;168:337–348.
   PubMed Web of Science ®Google Scholar
• Solmi M, Radua J, Olivola M, et al. Age at onset of mental disorders worldwide: large-scale meta-analysis of 192 epidemiological studies. Mol Psychiatry. 2022;27(1):281–295. DOI:10.1038/s41380-021-01161-7
   PubMed Web of Science ®Google Scholar
• Munjack DJ, Baltazar PL, DeQuattro V, et al. Generalized anxiety disorder: some biochemical aspects. Psychiatry Res. 1990;32(1):35–43. DOI:10.1016/0165-1781(90)90133-P
   PubMed Web of Science ®Google Scholar
• Abelson JL, Glitz D, Cameron OG, et al. Blunted growth hormone response to clonidine in patients with generalized anxiety disorder. Arch Gen Psychiatry. 1991;48(2):157–162. DOI:10.1001/archpsyc.1991.01810260065010
   PubMed Web of Science ®Google Scholar
• Garvey MJ, Noyes R, Woodman C, et al. Relationship of generalized anxiety symptoms to urinary 5-hydroxyindoleacetic acid and vanillylmandelic acid. Psychiatry Res. 1995;57(1):1–5. DOI:10.1016/0165-1781(94)02510-P
   PubMed Web of Science ®Google Scholar
• Schienle A, Wabnegger A. Chapter 8- structural and functional neuroanatomy of generalized anxiety disorder. In: Gerlach A Gloster A, editors. Generalized anxiety disorder and worrying: a comprehensive handbook for clinicians and researchers. Hoboken (NJ): John Wiley & Sons; 2020. p. 151–171.
   Google Scholar
• Baxter AJ, Scott KM, Vos T, et al. Global prevalence of anxiety disorders: a systematic review and meta-regression. Psychol Med. 2013;43(5):897–910. DOI:10.1017/S003329171200147X
   PubMed Web of Science ®Google Scholar
• Revicki DA, Travers K, Wyrwich KW, et al. Humanistic and economic burden of generalized anxiety disorder in North America and Europe. J Affect Disord. 2012;140(2):103–112. DOI:10.1016/j.jad.2011.11.014
   PubMed Web of Science ®Google Scholar
• Slee A, Nazareth I, Bondaronek P, et al. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. Lancet. 2019;393(10173):768–777. DOI:10.1016/S0140-6736(18)31793-8
   PubMed Web of Science ®Google Scholar
• Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50–55.
   PubMed Web of Science ®Google Scholar
• Cleare A, Pariante CM, Young AH, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2015;29(5):459–525. DOI:10.1177/0269881115581093
   PubMed Web of Science ®Google Scholar
• Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British association for psychopharmacology. J Psychopharmacol. 2014;28(5):403–439. DOI:10.1177/0269881114525674
   PubMed Web of Science ®Google Scholar
• Carvalho AF, Sharma MS, Brunoni AR, et al. The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: a critical review of the literature. Psychother Psychosom. 2016;85(5):270–288. DOI:10.1159/000447034
   PubMed Web of Science ®Google Scholar
• Rothmore J. Antidepressant-induced sexual dysfunction. Med J Aust. 2020;212(7):329–334.
   PubMed Web of Science ®Google Scholar
• Andrade C, Sandarsh S, Chethan KB, et al. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry. 2010;71(12):1565–1575. DOI:10.4088/JCP.09r05786blu
   PubMed Web of Science ®Google Scholar
• Beach SR, Celano CM, Sugrue AM, et al. QT prolongation, torsades de pointes, and psychotropic medications: a 5-year update. Psychosomatics. 2018;59(2):105–122. DOI:10.1016/j.psym.2017.10.009
   PubMed Web of Science ®Google Scholar
• Harvey BH, Slabbert FN. New insights on the antidepressant discontinuation syndrome. Hum Psychopharmacol. 2014;29(6):503–516.
   PubMed Web of Science ®Google Scholar
• Buoli M, Grassi S, Serati M, et al. Agomelatine for the treatment of generalized anxiety disorder. Expert Opin Pharmacother. 2017;18(13):1373–1379. DOI:10.1080/14656566.2017.1359257
   PubMed Web of Science ®Google Scholar
• Croom KF, Perry CM, Plosker GL. Mirtazapine: a review of its use in major depression and other psychiatric disorders. CNS Drugs. 2009;23(5):427–452.
   PubMed Web of Science ®Google Scholar
• Dawson LA, Watson JM. Vilazodone: a 5-HT1A receptor agonist/serotonin transporter inhibitor for the treatment of affective disorders. CNS Neurosci Ther. 2009;15(2):107–117.
   PubMed Web of Science ®Google Scholar
• Sanchez C, Asin KE, Artigas F. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol Ther. 2015;145:43–57.
   PubMed Web of Science ®Google Scholar
• Dhillon S, Yang LPH, Curran MP. Bupropion: a review of its use in the management of major depressive disorder. Drugs. 2008;68(5):653–689.
   PubMed Web of Science ®Google Scholar
• Huang X, Yang J, Yang S, et al. Role of tandospirone, a 5-HT1A receptor partial agonist, in the treatment of central nervous system disorders and the underlying mechanisms. Oncotarget. 2017;8(60):102705–102720. DOI:10.18632/oncotarget.22170
   PubMedGoogle Scholar
• Ortiz A, Pohl R, Gershon S. Azaspirodecanediones in generalized anxiety disorder: buspirone. J Affect Disord. 1987;13(2):131–143.
   PubMed Web of Science ®Google Scholar
• Micó JA, Prieto R. Elucidating the mechanism of action of pregabalin: α(2)δ as a therapeutic target in anxiety. CNS Drugs. 2012;26(8):637–648.
   PubMed Web of Science ®Google Scholar
• Frampton JE. Pregabalin: a review of its use in adults with generalized anxiety disorder. CNS Drugs. 2014;28(9):835–854.
   PubMed Web of Science ®Google Scholar
• Evoy KE, Sadrameli S, Contreras J, et al. Abuse and misuse of pregabalin and gabapentin: a systematic review update. Drugs. 2021;81(1):125–156. DOI:10.1007/s40265-020-01432-7
   PubMed Web of Science ®Google Scholar
• Baldwin DS, Masdrakis V. Non-prescribed use of gabapentinoids: mechanisms, predisposing factors, associated hazards and clinical management. Eur Neuropsychopharmacol. 2022;63:6–8.
   PubMed Web of Science ®Google Scholar
• Zaccara G, Gangemi P, Perucca P, et al. The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials. Epilepsia. 2011;52(4):826–836. DOI:10.1111/j.1528-1167.2010.02966.x
   PubMed Web of Science ®Google Scholar
• Schjerning O, Rosenzweig M, Pottegård A, et al. Abuse Potential of Pregabalin. CNS Drugs. 2016;30(1):9–25. DOI:10.1007/s40263-015-0303-6
   PubMed Web of Science ®Google Scholar
• Bonnet U, Scherbaum N. How addictive are gabapentin and pregabalin? A systematic review. Eur Neuropsychopharmacol. 2017;27(12):1185–1215.
   PubMed Web of Science ®Google Scholar
• Molero Y, Larsson H, D’Onofrio BM, et al. Associations between gabapentinoids and suicidal behaviour, unintentional overdoses, injuries, road traffic incidents, and violent crime: population based cohort study in Sweden. BMJ. 2019;365:l2147.
   PubMedGoogle Scholar
• Llorca PM, Spadone C, Sol O, et al. Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: a 3-month double-blind study. J Clin Psychiatry. 2002;63(11):1020–1027. DOI:10.4088/JCP.v63n1112
   PubMed Web of Science ®Google Scholar
• Lader M, Scotto J-C. A multicentre double-blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorder. Psychopharmacol (Berl). 1998;139(4):402–406.
   PubMed Web of Science ®Google Scholar
• Snowman AM, Snyder SH. Cetirizine: actions on neurotransmitter receptors. J Allergy Clin Immunol. 1990;86(6):1025–1028.
   PubMed Web of Science ®Google Scholar
• Meldrum BS, Chapman AG. Basic mechanisms of gabitril (tiagabine) and future potential developments. Epilepsia. 1999;40(9):S2–6.
   PubMedGoogle Scholar
• Nemeroff CB, Kinkead B, Goldstein J. Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. J Clin Psychiatry. 2002;63(13):5–11.
   PubMedGoogle Scholar
• Garver DL. Review of quetiapine side effects. J Clin Psychiatry. 2000;61(8): 31–33. discussion 34-35.
   PubMedGoogle Scholar
• López-Muñoz F, Álamo C, García-García P. The discovery of chlordiazepoxide and the clinical introduction of benzodiazepines: half a century of anxiolytic drugs. J Anxiety Disord. 2011;25(4):554–562.
   PubMed Web of Science ®Google Scholar
• Baldwin DS, Aitchison K, Bateson A, et al. Benzodiazepines: risks and benefits. A reconsideration. J Psychopharmacol. 2013;27(11):967–971. DOI:10.1177/0269881113503509
   PubMed Web of Science ®Google Scholar
• Soyka M, Longo DL. Treatment of Benzodiazepine Dependence. N Engl J Med. 2017;376(12):1147–1157.
   PubMed Web of Science ®Google Scholar
• Baldwin DS. Clinical management of withdrawal from benzodiazepine anxiolytic and hypnotic medications. Addiction. 2022;117(5):1472–1482.
   PubMed Web of Science ®Google Scholar
• Czobor P, Skolnick P, Beer B, et al. A multicenter, placebo-controlled, double-blind, randomized study of efficacy and safety of ocinaplon (DOV 273,547) in generalized anxiety disorder. CNS Neurosci Ther. 2010;16(2):63–75. DOI:10.1111/j.1755-5949.2009.00109.x
   PubMed Web of Science ®Google Scholar
• Bandelow B, Allgulander C, Baldwin DS, et al. World federation of societies of biological psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - Version 3. Part I: anxiety disorders. World J Biol Psychiatry. 2023;24(2):79–117.
   PubMed Web of Science ®Google Scholar
• Baldwin D, Woods R, Lawson R, et al. Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis. BMJ. 2011;342:d1199.
   PubMed Web of Science ®Google Scholar
• Bech P. Dose-response relationship of pregabalin in patients with generalized anxiety disorder. A pooled analysis of four placebo-controlled trials. Pharmacopsychiatry. 2007;40(4):163–168.
   PubMed Web of Science ®Google Scholar
• Roy-Byrne P. Treatment-refractory anxiety; definition, risk factors, and treatment challenges. Dialogues Clin Neurosci. 2015;17(2):191–206.
   PubMed Web of Science ®Google Scholar
• Howes OD, Thase ME, Pillinger T. Treatment resistance in psychiatry: state of the art and new directions. Mol Psychiatry. 2022;27(1):58–72.
   PubMed Web of Science ®Google Scholar
• Bokma WA, Wetzer GAAM, Gehrels JB, et al. Aligning the many definitions of treatment resistance in anxiety disorders: a systematic review. Depress Anxiety. 2019;36(9):801–812. DOI:10.1002/da.22895
   PubMed Web of Science ®Google Scholar
• Pollack MH, Simon NM, Zalta AK, et al. Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol Psychiatry. 2006;59(3):211–215. DOI:10.1016/j.biopsych.2005.07.005
   PubMed Web of Science ®Google Scholar
• Rickels K, Shiovitz TM, Ramey TS, et al. Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to SSRI or SNRI treatment. Int Clin Psychopharmacol. 2012;27(3):142–150. DOI:10.1097/YIC.0b013e328350b133
   PubMed Web of Science ®Google Scholar
• Chen TR, Huang HC, Hsu JH, et al. Pharmacological and psychological interventions for generalized anxiety disorder in adults: a network meta-analysis. J Psychiatr Res. 2019;118:73–83.
   PubMed Web of Science ®Google Scholar
• Newman MG, Basterfield C, Erickson TM, et al. Psychotherapeutic treatments for generalized anxiety disorder: cognitive and behavioral therapies, enhancement strategies, and emerging efforts. Expert Rev Neurother. 2022;22(9):751–770. DOI:10.1080/14737175.2022.2125800
   PubMed Web of Science ®Google Scholar
• Sala R, Goldstein BI, Morcillo C, et al. Course of comorbid anxiety disorders among adults with bipolar disorder in the U.S. population. J Psychiatr Res. 2012;46(7):865–872. DOI:10.1016/j.jpsychires.2012.03.024
   PubMed Web of Science ®Google Scholar
• Ross LE, McLean LM. Anxiety disorders during pregnancy and the postpartum period: a systematic review. J Clin Psychiatry. 2006;67(08):1285–1298.
   PubMedGoogle Scholar
• McAllister-Williams RH, Baldwin DS, Cantwell R, et al. British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017. J Psychopharmacol. 2017;31(5):519–552. DOI:10.1177/0269881117699361
   PubMed Web of Science ®Google Scholar
• Bryant C, Jackson H, Ames D. The prevalence of anxiety in older adults: methodological issues and a review of the literature. J Affect Disord. 2008;109(3):233–250.
   PubMed Web of Science ®Google Scholar
• Lenze EJ, Mulsant BH, Shear MK, et al. Efficacy and tolerability of citalopram in the treatment of late-life anxiety disorders: results from an 8-week randomized, placebo-controlled trial. Am J Psychiatry. 2005;162(1):146–150. DOI:10.1176/appi.ajp.162.1.146
   PubMed Web of Science ®Google Scholar
• Montgomery S, Chatamra K, Pauer L, et al. Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder. Br J Psychiatry J Ment Sci. 2008;193(5):389–394. DOI:10.1192/bjp.bp.107.037788
   PubMed Web of Science ®Google Scholar
• Mezhebovsky I, Mägi K, She F, et al. Double-blind, randomized study of extended release quetiapine fumarate (quetiapine XR) monotherapy in older patients with generalized anxiety disorder. Int J Geriatr Psychiatry. 2013;28(6):615–625. DOI:10.1002/gps.3867
   PubMed Web of Science ®Google Scholar
• Hall J, Kellett S, Berrios R, et al. Efficacy of cognitive behavioral therapy for generalized anxiety disorder in older adults: systematic review, meta-analysis, and meta-regression. Am J Geriatr Psychiatry. 2016;24(11):1063–1073. DOI:10.1016/j.jagp.2016.06.006
   PubMed Web of Science ®Google Scholar
• Green H, editor. Mental health of children and young people in Great Britain. Basingstoke: Palgrave Macmillan; 2005.
   Google Scholar
• Gale CK, Millichamp J. Generalised anxiety disorder in children and adolescents. BMJ Clin Evid. 2016;2016:1002.
   PubMedGoogle Scholar
• Strawn JR, Geracioti L, Rajdev N, et al. Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence-based treatment review. Expert Opin Pharmacother. 2018;19(10):1057–1070. DOI:10.1080/14656566.2018.1491966
   PubMed Web of Science ®Google Scholar
• Batelaan NM, Bosman RC, Muntingh A, et al. Risk of relapse after antidepressant discontinuation in anxiety disorders, obsessive-compulsive disorder, and post-traumatic stress disorder: systematic review and meta-analysis of relapse prevention trials. BMJ. 2017;358:j3927. DOI:10.1136/bmj.j3927
   PubMedGoogle Scholar
• Stocchi F, Nordera G, Jokinen RH, et al. Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. J Clin Psychiatry. 2003;64(3):250–258. DOI:10.4088/JCP.v64n0305
   PubMed Web of Science ®Google Scholar
• Allgulander C, Florea I, Huusom AKT. Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int J Neuropsychopharmacol. 2006;9(05):495–505.
   PubMedGoogle Scholar
• Davidson JRT, Wittchen HU, Llorca PM, et al. Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial. Eur Neuropsychopharmacol. 2008;18(9):673–681. DOI:10.1016/j.euroneuro.2008.05.002
   PubMed Web of Science ®Google Scholar
• Rickels K, Etemad B, Khalid-Khan S, et al. Time to relapse after 6 and 12 months’ treatment of generalized anxiety disorder with venlafaxine extended release. Arch Gen Psychiatry. 2010;67(12):1274–1281. DOI:10.1001/archgenpsychiatry.2010.170
   PubMed Web of Science ®Google Scholar
• Stein DJ, Ahokas A, Albarran C, et al. Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study. J Clin Psychiatry. 2012;73(07):1002–1008. DOI:10.4088/JCP.11m07493
   PubMedGoogle Scholar
• Baldwin DS, Loft H, Florea I. Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorder. Int Clin Psychopharmacol. 2012;27(4):197–207.
   PubMed Web of Science ®Google Scholar
• Feltner D, Wittchen H-U, Kavoussi R, et al. Long-term efficacy of pregabalin in generalized anxiety disorder. Int Clin Psychopharmacol. 2008;23(1):18–28. DOI:10.1097/YIC.0b013e3282f0f0d7
   PubMed Web of Science ®Google Scholar
• Katzman MA, Brawman-Mintzer O, Reyes EB, et al. Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial. Int Clin Psychopharmacol. 2011;26(1):11–24. DOI:10.1097/YIC.0b013e32833e34d9
   PubMed Web of Science ®Google Scholar
• Martin EI, Ressler KJ, Binder E, et al. The neurobiology of anxiety disorders: brain imaging, genetics, and psychoneuroendocrinology. Psychiatr Clin North Am. 2009;32(3):549–575. DOI:10.1016/j.psc.2009.05.004
   PubMed Web of Science ®Google Scholar
• Garakani A, Murrough JW, Freire RC, et al. Pharmacotherapy of anxiety disorders: current and emerging treatment options. Front Psychiatry. 2020;11:595584.
   PubMed Web of Science ®Google Scholar
• Michopoulos V, Powers A, Gillespie CF, et al. Inflammation in fear- and anxiety-based disorders: pTSD, GAD, and beyond. Neuropsychopharmacology. 2017;42(1):254–270. DOI:10.1038/npp.2016.146
   PubMed Web of Science ®Google Scholar
• Pecknold JC, Luthe L, Scott-Fleury MH, et al. Gepirone and the treatment of panic disorder: an open study. J Clin Psychopharmacol. 1993;13(2):145–149. DOI:10.1097/00004714-199304000-00009
   PubMed Web of Science ®Google Scholar
• Lin J, Su Y, Wang C, et al. Effects of tandospirone augmentation in major depressive disorder patients with high anxiety: a multicenter, randomized, parallel-controlled, open-label study. J Psychiatr Res. 2018;99:104–110.
   PubMed Web of Science ®Google Scholar
• Li Q, Zhang H, Lin G, et al. Relative safety and efficacy of two doses of tandospirone citrate for generalized anxiety disorder: a multicenter randomized controlled trial. Neuropsychiatr Dis Treat. 2022;18:1653–1664.
   PubMed Web of Science ®Google Scholar
• Fabre-Kramer pipeline [Internet]. Houston (TX): fabre-Kramer Pharmaceuticals; [cited 2023 Mar 15]. Available from: https://fabrekramer.com/pipeline/#1489503963784-5b2be039-5ceed3eb-d2400966-8526.
   Google Scholar
• Nichols DE, Barker EL. Psychedelics. Pharmacol Rev. 2016;68(2):264–355.
   PubMed Web of Science ®Google Scholar
• Kelmendi B, Kaye AP, Pittenger C, et al. Psychedelics. Curr Biol. 2022;32(2):R63–67. DOI:10.1016/j.cub.2021.12.009
   PubMed Web of Science ®Google Scholar
• Reiff CM, Richman EE, Nemeroff CB, et al. Psychedelics and psychedelic-assisted psychotherapy. Am J Psychiatry. 2020;177(5):391–410. DOI:10.1176/appi.ajp.2019.19010035
   PubMed Web of Science ®Google Scholar
• Ross S, Bossis A, Guss J, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016;30(12):1165–1180. DOI:10.1177/0269881116675512
   PubMed Web of Science ®Google Scholar
• Grob CS, Danforth AL, Chopra GS, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry. 2011;68(1):71–78. DOI:10.1001/archgenpsychiatry.2010.116
   PubMed Web of Science ®Google Scholar
• Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30(12):1181–1197. DOI:10.1177/0269881116675513
   PubMed Web of Science ®Google Scholar
• Holze F, Gasser P, Müller F, et al. Lysergic acid diethylamide–assisted therapy in patients with anxiety with and without a life-threatening illness: a randomized, double-blind, placebo-controlled phase II Study. Biol Psychiatry. 2023;93(3):215–223. DOI:10.1016/j.biopsych.2022.08.025
   PubMed Web of Science ®Google Scholar
• Skolnick P. Anxioselective anxiolytics: on a quest for the holy grail. Trends Pharmacol Sci. 2012;33(11):611–620.
   PubMed Web of Science ®Google Scholar
• Maramai S, Benchekroun M, Ward SE, et al. Subtype selective γ-aminobutyric acid type a receptor (GABAAR) modulators acting at the benzodiazepine binding site: an update. J Med Chem. 2020;63(7):3425–3446. DOI:10.1021/acs.jmedchem.9b01312
   PubMed Web of Science ®Google Scholar
• Atack JR. Subtype-selective GABA(A) receptor modulation yields a novel pharmacological profile: the design and development of TPA023. Adv Pharmacol. 2009;57:137–185.
   PubMedGoogle Scholar
• NCT00807937. Proof of concept in patients with generalized anxiety disorder (GAD)AZD7325 [Internet]. Bethesda (MD): U.S. National Library of Medicine; [cited 2023 Mar 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT00807937
   Google Scholar
• NCT00808249. AZD7325 proof of concept in patients with generalized anxiety disorder (GAD) [Internet]. Bethesda (MD): U.S. National Library of Medicine; [cited 2023 Mar 17]. Available from: https://www.clinicaltrials.gov/ct2/show/results/NCT00808249?view=results
   Google Scholar
• Simen A, Whitlock M, Qiu R, et al. An 8-week, randomized, phase 2, double-blind, sequential parallel-group comparison study of two dose levels of the gabaa positive allosteric modulator pf-06372865 compared with placebo as an adjunctive treatment in outpatients with inadequate response to standard of care for generalized anxiety disorder. J Clin Psychopharmacol. 2019;39(1):20–27. DOI:10.1097/JCP.0000000000000997
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Rosenblat JD, Nemeroff CB, et al. Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation. Am J Psychiatry. 2021;178(5):383–399. DOI:10.1176/appi.ajp.2020.20081251
   PubMed Web of Science ®Google Scholar
• Dean RL, Hurducas C, Hawton K, et al. Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder. Cochrane Database Syst Rev. 2021;9(11):CD011612. DOI:10.1002/14651858.CD011612.pub3
   PubMedGoogle Scholar
• Glue P, Medlicott NJ, Harland S, et al. Ketamine’s dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders. J Psychopharmacol. 2017;31(10):1302–1305. DOI:10.1177/0269881117705089
   PubMed Web of Science ®Google Scholar
• Glue P, Neehoff SM, Medlicott NJ, et al. Safety and efficacy of maintenance ketamine treatment in patients with treatment-refractory generalised anxiety and social anxiety disorders. J Psychopharmacol. 2018;32(6):663–667. DOI:10.1177/0269881118762073
   PubMed Web of Science ®Google Scholar
• Whittaker E, Dadabayev AR, Joshi SA, et al. Systematic review and meta-analysis of randomized controlled trials of ketamine in the treatment of refractory anxiety spectrum disorders. Ther Adv Psychopharmacol. 2021;11:20451253211056744.
   Web of Science ®Google Scholar
• Dunayevich E, Erickson J, Levine L, et al. Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder. Neuropsychopharmacology. 2008;33(7):1603–1610. DOI:10.1038/sj.npp.1301531
   PubMed Web of Science ®Google Scholar
• Kent JM, Daly E, Kezic I, et al. Efficacy and safety of an adjunctive mGlu2 receptor positive allosteric modulator to a SSRI/SNRI in anxious depression. Prog Neuropsychopharmacol Biol Psychiatry. 2016;67:66–73.
   PubMed Web of Science ®Google Scholar
• Reichmann F, Holzer P. Neuropeptide Y: a stressful review. Neuropeptides. 2016;55:99–109.
   PubMed Web of Science ®Google Scholar
• Sayed S, Van Dam NT, Horn SR, et al. A randomized dose-ranging study of neuropeptide Y in Patients with Posttraumatic Stress Disorder. Int J Neuropsychopharmacol. 2017;21(1):3–11. DOI:10.1093/ijnp/pyx109
   Web of Science ®Google Scholar
• De Biasi M, McLaughlin I, Klima ML. Chapter 18 - Nicotine and Neurokinin Signaling. In: Preedy V, editor. Neuropathology of drug addictions and substance misuse. volume 1: foundations of understanding, tobacco, alcohol, cannabinoids and opioids. Cambridge (MA): Academic Press; 2016. p. 189–200.
   Google Scholar
• Ebner K, Singewald N. The role of substance P in stress and anxiety responses. Amino Acids. 2006;31(3):251–272.
   PubMed Web of Science ®Google Scholar
• Michelson D, Hargreaves R, Alexander R, et al. Lack of efficacy of L-759274, a novel neurokinin 1 (substance P) receptor antagonist, for the treatment of generalized anxiety disorder. Int J Neuropsychopharmacol. 2013;16(1):1–11. DOI:10.1017/S1461145712000065
   PubMed Web of Science ®Google Scholar
• Tauscher J, Kielbasa W, Iyengar S, et al. Development of the 2nd generation neurokinin-1 receptor antagonist LY686017 for social anxiety disorder. Eur Neuropsychopharmacol. 2010;20(2):80–87. DOI:10.1016/j.euroneuro.2009.10.005
   PubMed Web of Science ®Google Scholar
• Mathew SJ, Vythilingam M, Murrough JW, et al. A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial. Eur Neuropsychopharmacol. 2011;21(3):221–229. DOI:10.1016/j.euroneuro.2010.11.012
   PubMed Web of Science ®Google Scholar
• Risbrough VB, Stein MB. Role of corticotropin releasing factor in anxiety disorders: a translational research perspective. Horm Behav. 2006;50(4):550–561.
   PubMed Web of Science ®Google Scholar
• Spierling SR, Zorrilla EP. Don’t stress about CRF: assessing the translational failures of CRF1 antagonists. Psychopharmacol (Berl). 2017;234(9–10):1467–1481.
   PubMed Web of Science ®Google Scholar
• Coric V, Feldman HH, Oren DA, et al. Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder. Depress Anxiety. 2010;27(5):417–425. DOI:10.1002/da.20695
   PubMed Web of Science ®Google Scholar
• Freeman SM, Inoue K, Smith AL, et al. The neuroanatomical distribution of oxytocin receptor binding and mRNA in the male rhesus macaque (Macaca mulatta). Psychoneuroendocrinology. 2014;45:128–141.
   PubMed Web of Science ®Google Scholar
• Naja WJ, Aoun MP. Oxytocin and anxiety disorders: translational and therapeutic aspects. Curr Psychiatry Rep. 2017;19(10):67.
   PubMed Web of Science ®Google Scholar
• Neumann ID, Slattery DA. Oxytocin in general anxiety and social fear: a translational approach. Biol Psychiatry. 2016;79(3):213–221.
   PubMed Web of Science ®Google Scholar
• Serrano VF, MacDonald K, McKinney R, et al. A randomized, placebo-controlled investigation of intranasal oxytocin in patients with anxiety. Neuropsychopharmacology. 2011;36:S324–449.
   Google Scholar
• Chieffi S, Carotenuto M, Monda V, et al. Orexin system: the key for a healthy life. Front Physiol. 2017;8:357.
   PubMed Web of Science ®Google Scholar
• Tsujino N, Sakurai T. Role of orexin in modulating arousal, feeding, and motivation. Front Behav Neurosci. 2013;7:28.
   PubMed Web of Science ®Google Scholar
• Geiger MJ, Neufang S, Stein DJ, et al. Arousal and the attentional network in panic disorder. Hum Psychopharmacol. 2014;29(6):599–603. DOI:10.1002/hup.2436
   PubMed Web of Science ®Google Scholar
• Flores Á, Saravia R, Maldonado R, et al. Orexins and fear: implications for the treatment of anxiety disorders. Trends Neurosci. 2015;38(9):550–559. DOI:10.1016/j.tins.2015.06.005
   PubMed Web of Science ®Google Scholar
• Johnson PL, Truitt W, Fitz SD, et al. A key role for orexin in panic anxiety. Nat Med. 2010;16(1):111–115. DOI:10.1038/nm.2075
   PubMed Web of Science ®Google Scholar
• Akça ÖF, Uzun N, Kılınç İ. Orexin a in adolescents with anxiety disorders. Int J Psychiatry Clin Pract. 2020;24(2):127–134.
   PubMed Web of Science ®Google Scholar
• Gottschalk MG, Richter J, Ziegler C, et al. Orexin in the anxiety spectrum: association of a HCRTR1 polymorphism with panic disorder/agoraphobia, CBT treatment response and fear-related intermediate phenotypes. Transl Psychiatry. 2019;9(1):75. DOI:10.1038/s41398-019-0415-8
   PubMed Web of Science ®Google Scholar
• Salvadore G, Bonaventure P, Shekhar A, et al. Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans. Transl Psychiatry. 2020;10(1):308. DOI:10.1038/s41398-020-00937-9
   PubMed Web of Science ®Google Scholar
• Kaufmann P, Ort M, Golor G, et al. Multiple-dose clinical pharmacology of the selective orexin-1 receptor antagonist ACT-539313. Prog Neuropsychopharmacol Biol Psychiatry. 2021;108:110166.
   PubMed Web of Science ®Google Scholar
• Gorka SM, Khorrami KJ, Manzler CA, et al. Acute orexin antagonism selectively modulates anticipatory anxiety in humans: implications for addiction and anxiety. Transl Psychiatry. 2022;12(1):308. DOI:10.1038/s41398-022-02090-x
   PubMed Web of Science ®Google Scholar
• Nakamura M, Nagamine T. Neuroendocrine, autonomic, and metabolic responses to an orexin antagonist, suvorexant, in psychiatric patients with insomnia. Innov Clin Neurosci. 2017;14(3–4):30–37.
   PubMedGoogle Scholar
• Fagan H, Jones E, Baldwin DS. Orexin receptor antagonists in the treatment of depression: a leading article summarising pre-clinical and clinical studies. CNS Drugs. 2023;37(1):1–12.
   PubMed Web of Science ®Google Scholar
• Crocq MA. History of cannabis and the endocannabinoid system. Dialogues Clin Neurosci. 2020;22(3):223–228.
   PubMed Web of Science ®Google Scholar
• Izzo AA, Borrelli F, Capasso R, et al. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci. 2009;30(10):515–527. DOI:10.1016/j.tips.2009.07.006
   PubMed Web of Science ®Google Scholar
• Blessing EM, Steenkamp MM, Manzanares J, et al. Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics. 2015;12(4):825–836. DOI:10.1007/s13311-015-0387-1
   PubMed Web of Science ®Google Scholar
• Black N, Stockings E, Campbell G, et al. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Lancet Psychiatry. 2019;6(12):995–1010. DOI:10.1016/S2215-0366(19)30401-8
   PubMed Web of Science ®Google Scholar
• Bergamaschi MM, Queiroz RHC, Chagas MHN, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology. 2011;36(6):1219–1226. DOI:10.1038/npp.2011.6
   PubMed Web of Science ®Google Scholar
• Jetly R, Heber A, Fraser G, et al. The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: a preliminary randomized, double-blind, placebo-controlled cross-over design study. Psychoneuroendocrinology. 2015;51:585–588.
   PubMed Web of Science ®Google Scholar
• Hou R, Baldwin DS. A neuroimmunological perspective on anxiety disorders. Hum Psychopharmacol. 2012;27(1):6–14.
   PubMed Web of Science ®Google Scholar
• Costello H, Gould RL, Abrol E, et al. Systematic review and meta-analysis of the association between peripheral inflammatory cytokines and generalised anxiety disorder. BMJ Open. 2019;9(7):e027925. DOI:10.1136/bmjopen-2018-027925
   PubMed Web of Science ®Google Scholar
• Hou R, Ye G, Liu Y, et al. Effects of SSRIs on peripheral inflammatory cytokines in patients with generalized anxiety disorder. Brain Behav Immun. 2019;81:105–110.
   PubMed Web of Science ®Google Scholar
• Mirzaei E, Mirjalili M, Jahangard L, et al. Influence of simvastatin as augmentative therapy in the treatment of generalized anxiety disorder: a pilot randomized, placebo-controlled study. Neuropsychobiology. 2021;80:242–252.
   PubMed Web of Science ®Google Scholar
• Kim S-W, Kang H-J, Jhon M, et al. Statins and Inflammation: new Therapeutic Opportunities in Psychiatry. Front Psychiatry. 2019;10:103.
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905–1917. DOI:10.1176/ajp.2006.163.11.1905
   PubMed Web of Science ®Google Scholar
• Correll CU, Solmi M, Cortese S, et al. The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de-risk trial programmes of novel agents. World Psychiatry. 2023;22(1):48–74. DOI:10.1002/wps.21056
   PubMed Web of Science ®Google Scholar
• Baldwin DS, Hou R, Gordon R, et al. Pharmacotherapy in generalized anxiety disorder: novel experimental medicine models and emerging drug targets. CNS Drugs. 2017;31(4):307–317. DOI:10.1007/s40263-017-0423-2
   PubMed Web of Science ®Google Scholar
• Grillon C, Robinson OJ, Cornwell B, et al. Modeling anxiety in healthy humans: a key intermediate bridge between basic and clinical sciences. Neuropsychopharmacology. 2019;44(12):1999–2010. DOI:10.1038/s41386-019-0445-1
   PubMed Web of Science ®Google Scholar
• Bailey JE, Dawson GR, Dourish CT, et al. Validating the inhalation of 7.5% CO 2 in healthy volunteers as a human experimental medicine: a model of generalized anxiety disorder (GAD). J Psychopharmacol. 2011;25(9):1192–1198. DOI:10.1177/0269881111408455
   PubMed Web of Science ®Google Scholar
• Schmitz A, Grillon C. Assessing fear and anxiety in humans using the threat of predictable and unpredictable aversive events (the NPU-threat test). Nat Protoc. 2012;7(3):527–532.
   PubMed Web of Science ®Google Scholar
• Kirschbaum C, Pirke KM, Hellhammer DH. The ‘trier social stress test’ – a tool for investigating psychobiological stress responses in a laboratory setting. Neuropsychobiology. 1993;28(1–2):76–81.
   PubMed Web of Science ®Google Scholar
• Biedermann SV, Biedermann DG, Wenzlaff F, et al. An elevated plus-maze in mixed reality for studying human anxiety-related behavior. BMC Biol. 2017;15(1):125. DOI:10.1186/s12915-017-0463-6
   PubMedGoogle Scholar